Article

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscle

2023-02-03

Abstract excerpt

Modulating myosin function is a novel therapeutic approach in patients with cardiomyopathy. Detailed mechanism of action of these agents can help predict potential unwanted affects and identify patient populations that can benefit most from them. Danicamtiv is a novel myosin activator with promising preclinical data that is currently in clinical trials. While it is known danicamtiv increases force and cardiomyocyt...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1437fdcd-0789-5170-b548-0400b5031dc3
DOI: 10.1101/2023.01.31.526380

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Danicamtiv increases myosin recruitment and alters the chemomechanical cross bridge cycle in cardiac muscleDOI 10.1101/2023.01.31.526380Read

Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.Semantic proximity Read

Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy.Semantic proximity Read

A therapeutic leap: how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions.Semantic proximity Read

Mavacamten stabilizes the auto-inhibited state of two-headed cardiac myosinSemantic proximity Read

Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca2+, and activate NFAT and Akt signaling.Semantic proximity Read

Direct measurement of mavacamten and deoxyATP perturbation of the SRX/DRX ratio in porcine cardiac myofibrils using a simple, accessible and multiplexed approachSemantic proximity Read

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEFSemantic proximity Read

Targeting the sarcomere in inherited cardiomyopathies.Semantic proximity Read

CONSERVED INTERACTIONS IN CARDIAC SYNTHETIC THICK FILAMENTS DIFFERENTLY AFFECT MYOSIN SUPER-RELAXED STATE IN HEALTHY, DISEASE AND MAVACAMTEN-TREATED MODELSSemantic proximity Read

Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy.Semantic proximity Read

Controlling load-dependent kinetics of β-cardiac myosin at the single-molecule level.Semantic proximity Read

The dilated cardiomyopathy-causing mutation ACTC E361G in cardiac muscle myofibrils specifically abolishes modulation of Ca(2+) regulation by phosphorylation of troponin I.Semantic proximity Read